HENT1、NF-κB Expression In Diffuse Large B Cell Lymphoma And Its Significance

Purpose Nucleoside transporter(NTs) play an important role in the process of thetransporting of the nucleoside and mediated nucleotide type drugs. The leading role ofhuman equilibrative nucleotide transporters1(hENT1) in the transported nucleosidedrugs has been comfirmed. This study was designed to investigate the expression andsignificance of the human equilibrative nucleoside transporters1in the germinal centerB cell-like （GCB）and non-GCB types diffuse large B-cell lymphoma.Methods Collected82examples of DLBCL and10of lymph node reactive hyperplasiatissue, and made into paraffin tissue sections. Observed the expression of the CD10,bc1-6, MUM1proteins and divided the DLBCL into germinal center B cell-like（GCB）and non-germinal center B cell-like （non-GCB）using immunohistochemistry, anddetected the expression of hENT1to investigate the connection of theimmunohistochemical results and clinical parameters including disease prognosis.Results （1）The examples of the GCB type was17in all DLBCL, while the examles ofnon-GCB was65.(2) hENT1expressed in all the examples of the lymph node reactivehyperplasia tissue. The positive expression rate of the hENT1protein in the DLBCLwas31.71%(26/82), and hENT1protein expression rate in DLBCL GCB(52.94%) washigher than in non-GCB(26.15%), hENT1protein expression in DLBCL GCB andnon-GCB subtype showed significant difference（P=0.031,P<0.05）.（3） The differentexpression of hENT1in gender, age, location, the level of LDH, Ann Arbor staging,with or without B symptoms showed no significant in statistics.（4） In these76cases, the median of the follow-up time was21（0.5～73）months and the death rate was60.53%. The medians of the follow-up time of the GCB and non-GCB type were28(0.5-64) and23(1-73) months, respectively. The cumulative survival difference of theGCB and non-GCB group was significant in statistics（P=0.010）using Log-rank test.The medians of the follow-up time of hENT(+) and hENT(-) were27（10～64）and34（4～58）months in GCB group, while in non-GCB group were15(0.5~55) and21(1~73) months, respectively, which the cumulative survival differences were notsignificant in statistics(P=0.088and P=0.508, respectively).Conclusion The number of the non-GCB types of the DLBCL patients has a largerproportion and their prognosis is poor. In the treatment, detecting the expression ofhENT1can provide a theoretical basis for using nucleoside drug or not. Purposes Nuclear transcription factor κB(NF-κB),which is constituted by complicatedpolypeptide subunits and exists in eucaryon cells widely, is a member of theeukaryocyte transcription factor Rel protein family and a member of inducibletranscription factor family. Five members of NF-κB/Rel has been found in mammaliancell so far. NF-κB is provided with very important function. It is connected withactivation of the immune cell, the development of the T and B lymphocytic, and cellactivity such as cell proliferation and apoptosis and so on. The unusual activation ofNF-κB has been found in many tumours. The abnormal activation or completelyinhibition is connected with the occurrence of many diseases. This study was designedto investigate the expression and significance of the NF-κB in the germinal center Bcell-like （GCB）and non-GCB types diffuse large B-cell lymphoma.Methods Collected82examples of DLBCL and made into paraffin tissue sections.Observed the expression of the CD10, bc1-6, MUM1proteins and divided the DLBCLinto germinal center B cell-like（GCB）and non-germinal center B cell-like（non-GCB）using immunohistochemistry, and detected the expression of NF-κB to investigate theconnection of the immunohistochemical results and clinical parameters includingdisease prognosis.Results （1）The positive rate of the NF-κB in all82DLBCL examples was50%(41/82). In all examples of the NF-κB positive patients, GCB type was4and thepositive rate was23.53%(4/17), while non-GCB was37and the positive rate was56.92%(37/65) in all DLBCL, and the difference was significant instatistics(P=0.041<0.05). The expression of NF-κB in DLBCL non-GCB was higher than in GCB. In the41positive NF-κB patients,20was in lymphonodus, and21wasout of lymphonodus, the positive rates were68.97%（20/29）and39.62%（21/53）,respectively, and the difference was significant in statistics(P=0.01<0.05). NF-κB inlymphonodus was higher than out of lymphonodus in DLBCL. The expression ofNF-κB was not connected with gender, age, location, the level of LDH, Ann Arborstaging and with or without B symptoms(P>0.05).(2) In these76cases, the median of the follow-up time was21（0.5～73）months andthe death rate was60.53%. The medians of the follow-up time of the NF-κB(+) andNF-κB(-) type were14(0.5-73) and24(1-73) months, respectively. The cumulativesurvival difference was not significant in statistics（P=0.262）using Log-rank test. Themedians of the follow-up time of NF-κB (+) and NF-κB (-) were21（10～64）and27（4～61）months in GCB group, while in non-GCB group were14(0.5~73) and22(1~73) months, respectively, which the cumulative survival differences were notsignificant in statistics(P=0.260and P=0.387, respectively).Conclusion Detection NF-κB could be an index of DLBCL patients with bad clinicalfeatures and poorer prognosis, and it could be conducive to guide individualizationdrug therapy.